Match Document Document Title
RE44916 Canine influenza virus and related compositions and methods of use  
The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4,...
8728515 Adjuvants for use in vaccination  
A compound of formula (I) for use as an adjuvant in vaccination; wherein R is an optionally-substituted alkyl, alkenyl, alkynyl, aryl, arylalkyl or alkylaryl moiety having from 1 to 50 carbon...
8728748 HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders  
The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid...
8728491 Transcutaneous delivery of therapeutic agents  
The present invention provides materials and methods to facilitate the transcutaneous delivery of therapeutic agents. In some embodiments, agonists of tight junctions are used in compositions to...
8728486 Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds  
The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using...
8728806 Methods and compositions related to Th-1 dendritic cells  
Certain embodiments of the invention are directed to methods for inducing an immunologic response to a tumor in a patient using mature dendritic cells transfected with a nucleic acid composition...
8728456 Programming of cells for tolerogenic therapies  
Biomaterial systems, e.g., gel scaffolds, are used in vivo to recruit immune cells and promote their activation towards a non-inflammatory phenotype, thereby leading suppression of inflammation....
8722052 Vaccinia virus protein A46 peptide and use thereof  
A peptide for inhibiting Toll-like receptor 4 (TLR4) signalling comprising the amino acid sequence of SEQ ID NO. 4, SEQ ID NO 55, SEQ ID NO 68, SEQ ID NO. 69, SEQ ID NO 70, SEQ ID NO 71, SEQ ID NO...
8722082 Lipids and compositions for the delivery of therapeutics  
The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having...
8722871 VMP-like sequences of pathogenic borrelia species and strains  
The present invention relates to DNA sequences encoding Vmp-like polypeptides of pathogenic Borrelia, the use of the DNA sequences in recombinant vectors to express polypeptides, the encoded amino...
8722061 Antibody profiles characteristic of tuberculosis state  
Serum antibody assays capable of distinguishing cases of inactive TB from cases of active TB include a combination of at least three M. tuberculosis protein antigens, at least one for which a...
8722062 Multivalent meningococcal polysaccharide-protein conjugate vaccine  
The present invention describes a combined vaccine that offers broad protection against meningococcal disease caused by the pathogenic bacteria Neisseria meningitidis. The vaccine is comprised of...
8715677 Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy  
Methods of enhancing immune response to an immunogen in a subject are disclosed. Also disclosed are methods of reducing the sensitivity to an allergen in a subject. The methods comprise the...
8715697 Genes associated with Leishmania parasite virulence  
The invention relates to the field of combating leishmaniases. Said invention results from the isolation, from wild isolates of Leishmania major, of a protein-coding gene known as LmPDI which has...
8715678 Method for inhibiting the formation of SET1 family core complexes  
Disclosed in this specification is a method for inhibiting the formation of vertebrate SET1 family core complexes. A guanidinium-containing molecule is used to competitively inhibit the binding of...
8716253 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes  
The invention relates to the therapeutic use of oligonucleotides or oligonucleotide analogs as immunostimulatory agents in immunotherapy applications. The invention provides methods for enhancing...
8715620 Treatment of asthma in mammals with clostridia neurotoxins  
A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the...
8715698 Truncated secretory aspartyl proteinase 2  
The present invention relates to an isolated truncated form of the secretory aspartyl proteinase 2, as well as to nucleic acid molecules encoding same. The present invention also relates to a...
8716012 Alpha thymosin peptides as vaccine enhancers  
The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised...
8715638 Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections  
The present invention provides compounds of Formula (A): (Chemical formula should be inserted here as it appears on abstract in paper form) (A) and tautomers, isomers, and esters of said...
8715693 Neurovirulent strain of the West Nile virus and uses thereof  
Neuroinvasive and neurovirulent strain of the West Nile virus, named IS-98-ST1, nucleic acid molecules derived from its genome, proteins and peptides encoded by said nucleic acid molecules, and...
8715653 Modulation of Rhamm (CD168) for selective adipose tissue development  
Herein is described the methods and compositions for modulation of Rhamm, also known as CD 186, and its effects on wound repair, muscle differentiation, bone density and adipogeneisis through its...
8715659 Single domain brain-targeting antibody fragments derived from llama antibodies  
A phage-displayed library of llama single heavy domain antibodies (sdAbs) was enriched for species that selectively bind to and are internalized by human cerebromicrovascular endothelial cells...
8715695 Polypeptide fragments of the hepatitis E virus, the vaccine composition comprising said fragments and the diagnostic kits  
The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric...
8716254 DNA vaccines against tumor growth and methods of use thereof  
A DNA vaccine suitable for eliciting an immune response against cancer cells comprises a DNA construct operably encoding a cancer-associated Inhibitor of Apoptosis-family protein and an...
8716000 Inactivating pathogens with oxidizing agents for vaccine production  
The present disclosure provides methods for producing a vaccine composition containing a pathogen that is rendered noninfectious by exposure to hydrogen peroxide. The methods disclosed herein are...
8709710 Methods of modulating interleukin-22 and immune response by notch regulators  
The invention relates to the use of notch regulators for modulating IL-22 production in T-cells, by influencing the activity or activation of the notch signal path. The invention further relates...
8709446 HYR1 as a target for active and passive immunization against Candida  
The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis.
8709433 Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate  
A method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer...
8709447 Compositions and methods for activating innate and allergic immunity  
Methods for making and using therapeutic formulations of Proteosome-based immunoactive compositions are provided. The immunogenic compositions, which include Proteosomes and liposaccharides, may...
8703908 Expression and export of angiogenesis inhibitors as immunofusins  
A fusion protein of the invention comprises an immunoglobulin Fc region and a first target protein linked to the immunoglobulin Fc region. The first target protein comprises a collagen XVIII...
8703143 Antibodies of the ED-B domain of fibronectin, their construction and uses  
According to the present invention there is provided a specific binding member which is specific for and binds directly to the ED-B oncofoetal domain of fibronectin (FN). The invention also...
8703695 Biologically active peptides and their new uses  
Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.
8703432 Recombinant Treponema spp. proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same  
The present invention relates to proteins and/or fragments and derivatives thereof and their use as vaccines and in biotechnological methods. The vaccines particularly include immunogenic proteins...
8703151 Tuberculosis vaccines comprising antigens expressed during the latent infection phase  
The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M....
8703148 Immunogenic composition  
The present application relates to immunogenic compositions comprising staphylococcal PNAG which is less than 40% N-acetylated and is conjugated to a carrier protein by a linker bonded to an amine...
8703153 Salmonella vectored vaccines against Chlamydia and methods of use  
The invention provides an attenuated Salmonella vaccine vector comprising one or more heterologous polynucleotides that encode immunogenic Chlamydial peptides. In one embodiment, the attenuated...
8703142 Methods to bypass CD4+ cells in the induction of an immune response  
Embodiments of the invention disclosed herein relate to methods and compositions for bypassing the involvement of CD4+ cells when generating antibody and MHC class I-restricted immune responses,...
8703147 Methods and compositions for treating and preventing malaria (2)  
The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by Plasmodium falciparum, such as malaria. The...
8703152 Methods of treating inflammatory intestinal disease and managing symptoms thereof  
Methods and products are disclosed for treating an inflammatory intestinal disease in a mammalian subject in need thereof, or preventing or reducing a symptom of inflammatory intestinal disease....
8703921 Compositions and methods for delivering inhibitory oligonucleotides  
The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide...
8697060 Treatment method for relapsing-remitting multiple sclerosis  
Disclosed is a method for treating relapsing-remitting multiple sclerosis in a patient by administering to the patient autologous, ex vivo-expanded CD4+CD25+Foxp3+CD127low T reg cells when the...
8697081 Method of modulating neovascularization  
The invention provides a method of inhibiting neovascularization in a subject. The method comprises administering to the subject an agent that interferes with fibronectin (Fn) matrix assembly in...
8697848 Method for reducing immunogenicity of therapeutic protein compositions  
The present invention provides methods for reducing and/or evaluating the immunogenic potential of a therapeutic protein preparation. The present invention further provides pharmaceutical...
8697091 Mycobacterium antigens  
There is provided a diagnostic reagent for use in the detection of M. bovis or M. tuberculosis infection in an animal, comprising a peptide which has an epitope from Mycobacterium bovis hypothetic...
8697104 Apparatus, system, and method for creating immunologically enhanced spaces in-vivo  
The present invention creates an immunologically protected/enhanced space in viva in a mammal by removing the impact of soluble inhibitors of the mammal's immune system in a defined space within...
8694265 Bioinformatic approach to disease diagnosis  
A kit and test panel utilizing a multivariate diagnostic method based on optimizing diagnostic likelihood ratios through the effective use of multiple diagnostic tests is disclosed. The...
8691502 T-cell vaccination with viral vectors via mechanical epidermal disruption  
Attenuated, replication-deficient viruses such as vaccinia viruses are used to deliver an exogenous viral, bacterial, parasitic or tumor antigen to an epidermal tissue such as the skin, lungs or...
8691243 Protein-based Streptococcus pneumoniae vaccine  
Vaccine compositions and methods for protecting a mammalian subject against infection with S. pneumoniae are disclosed. The vaccines and methods comprise an effective amount of one or more...
8691283 Standardized bee venom preparation  
Bee venom may be administered in a standardized formulation with or without relatively small amounts of anesthetic. In particular, the results of the combination of venom and anesthetic...